Tag
A concise, practice-focused summary of the 2026 GINA Strategy Report, highlighting new recommendations on inhaled corticosteroid–formoterol (AIR) strategies, severe asthma biologic guidance, and acute care updates.
Sputum eosinophilia is linked to increased asthma-specific health services use, while neutrophilic inflammation drives hospitalizations in COPD. Understanding these inflammatory patterns aids personalized management and resource planning.
Dupilumab treatment in moderate to severe asthma significantly reduces mucus plug burden, resolves existing plugs, limits new plug formation, and decreases plug radiodensity on CT scans, correlating with improved lung function and ventilati
This article reviews exploratory analyses from a phase 2b trial examining eosinophil count changes in adults with uncontrolled moderate-to-severe asthma treated with the IL-4Rα inhibitor rademikibart, indicating a low risk of treatment-emer
This review summarizes the progression risk from mild-to-moderate to severe asthma based on the NORDSTAR cohort and integrates emerging evidence on biologic therapies that improve severe asthma outcomes across diverse patient profiles.
A novel conversation aid was developed and refined iteratively with patients and physicians to support shared decision-making for low carbon footprint inhaler prescribing in asthma and COPD, balancing environmental impact with safety and pa
In Puerto Rican youth, an unhealthy diet was linked to higher odds of T17-high asthma, suggesting diet may influence asthma through immune pathways beyond allergy-related inflammation.
The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new ev
Three complementary studies—EVEREST (head‑to‑head RCT), the US ADVANTAGE real‑world study, and a target‑trial emulation—consistently show greater reductions in nasal polyp burden, smell loss, asthma exacerbations, and systemic steroid use w
This study reveals multiple distinct molecular mechanisms, including epithelial and macrophage pathways, that contribute to residual asthma exacerbations in children treated with mepolizumab, highlighting the complexity of airway inflammati
The CARE trial shows that budesonide-formoterol reliever monotherapy significantly reduces asthma attack rates compared to salbutamol in children aged 5-15 years with mild asthma, with comparable safety over 52 weeks.
Longitudinal data from the French NutriNet-Santé cohort reveal that persistent and increased use of green cleaning products is associated with a modest but significant rise in asthma symptoms, underscoring the need for cautious use and pati
This study demonstrates that asthma modestly increases the risk of degenerative valvular heart diseases, highlighting the need for cardiovascular vigilance in asthmatic individuals.
A randomized clinical trial demonstrates that an Acceptance and Commitment Therapy-based parenting program reduces health care use, improves asthma control, and alleviates ADHD symptoms in children with both conditions.
As-needed albuterol–budesonide significantly reduces severe exacerbations in mild asthma compared to albuterol alone, with comparable safety. Two pivotal trials confirm efficacy across lung function and exacerbation outcomes.
A randomized trial finds that subcutaneous cockroach immunotherapy effectively downregulates dominant T-cell responses in pediatric asthma, independent of allergen abundance in the therapeutic extract.
A randomized trial shows that a smartphone-based asthma self-management program improves symptom control in adults, though its effectiveness is attenuated in African American participants.
